Private ultra-thin DSAEK endothelial graft UK 2026 — corneal endothelial keratoplasty London

What is ultra-thin DSAEK (UT-DSAEK)?

DSAEK (Descemet's stripping automated endothelial keratoplasty) is a partial-thickness corneal transplant that replaces only the failed inner endothelial layer of the cornea, leaving the anterior cornea undisturbed. The procedure was first described by Melles in the early 2000s and rapidly displaced penetrating keratoplasty (full-thickness corneal transplant) as the standard of care for isolated corneal endothelial dysfunction, because it preserves the anterior corneal stroma, requires no full-thickness sutures, avoids the substantial astigmatism associated with PKP, has a much lower rejection rate, and recovers faster with a more predictable visual outcome.

Conventional DSAEK uses a donor lenticule typically 130 to 200 microns thick. Ultra-thin DSAEK (UT-DSAEK) uses a donor lenticule prepared by double-pass microkeratome dissection in the eye bank or in the operating theatre to a thickness of less than 100 microns (some series use less than 130 microns as the cut-off; rigorous studies and the DETECT trial use less than 100 microns). The thinner donor optimises visual recovery and post-operative best corrected visual acuity, narrowing but not eliminating the visual advantage of DMEK (Descemet membrane endothelial keratoplasty) which transplants only the 10 to 15 micron Descemet membrane and endothelium with no stroma at all. UT-DSAEK retains the technical advantages of DSAEK over DMEK: a more robust donor that is easier to unfold and orient correctly in the anterior chamber, a much lower graft detachment rate, easier handling in eyes with complex anterior segment anatomy, and a less steep learning curve.

UT-DSAEK is delivered as a day-case procedure under topical or sub-Tenon's local anaesthetic. Theatre time is approximately 30 to 45 minutes (60 to 90 minutes for the triple procedure of combined cataract surgery with intra-ocular lens implant plus UT-DSAEK). Two paracentesis side ports and a 3.0 to 3.2 mm clear-cornea main incision are constructed. The recipient endothelium and Descemet membrane are stripped en bloc over an 8 to 9 mm diameter ('descemetorrhexis'). The donor lenticule is inserted through the main wound using a Busin glide or pull-through technique, unfolded and centred in the anterior chamber. An air bubble (or 20 per cent SF6 / 14 per cent C3F8 gas) tamponades the lenticule against the recipient cornea. Same-day discharge is routine. The patient maintains supine face-up positioning for 24 to 72 hours after surgery to allow the bubble to hold the graft in place. Vision is blurred for the first 1 to 2 weeks while the bubble dissipates, then improves over weeks to months; final BCVA is usually reached by 6 months. Long-term topical steroid maintenance and graft surveillance are required.

UK 2026 ultra-thin DSAEK pricing, in detail

Private UT-DSAEK pricing in the UK is driven by the CQC-registered ophthalmic theatre overhead, the consultant corneal surgeon's seniority and experience, the eye bank donor tissue cost (NHSBT TES tissue-sales fee or imported tissue via Human Tissue Authority licensed pathway, often pre-cut to ultra-thin specification), the anaesthetic and theatre support, and the structured 12-month follow-up schedule. Most reputable London corneal centres bundle these components into an all-inclusive per-eye fee.

For related corneal pathways see our DMEK corneal graft, penetrating keratoplasty, Fuchs endothelial dystrophy, pseudophakic bullous keratopathy, corneal dystrophies and our corneal transplant overview.

What a quality UK ultra-thin DSAEK package should include

• Consultant corneal surgeon — a UK GMC-registered consultant ophthalmologist with documented corneal and external eye disease fellowship, an active endothelial keratoplasty practice (DSAEK, UT-DSAEK and DMEK) with a minimum 30 to 50 endothelial keratoplasties per year and a demonstrable familiarity with complex anterior segments.
• Full pre-operative work-up — best corrected visual acuity, manifest and cycloplegic refraction, slit-lamp documentation of guttae and oedema, IOP (Goldmann), dilated fundus examination, central and peripheral corneal pachymetry, anterior segment OCT documenting corneal thickness profile, specular microscopy of the corneal endothelium documenting cell density and morphology, Scheimpflug tomography where indicated, lens status and biometry if combined cataract surgery is planned, macular OCT to rule out concurrent retinal pathology limiting visual potential.
• CQC-registered ophthalmic operating theatre — with laminar flow, dedicated ophthalmic surgical equipment, theatre nurses experienced in endothelial keratoplasty, on-site anaesthetic support and recovery facilities.
• Eye bank donor tissue from a recognised source — NHS Blood and Transplant Tissue and Eye Services (NHSBT TES) Manchester or Liverpool, or imported from an accredited European or US eye bank under Human Tissue Authority licensing. All tissue screened for transmissible disease and endothelial cell count assessed. Pre-cut ultra-thin specification preferred.
• Default topical or sub-Tenon's anaesthetic — with mild oral sedation; general anaesthetic reserved for patients unable to cooperate.
• Standardised surgical technique — 3.0 to 3.2 mm clear-cornea main wound, paracentesis side ports, descemetorrhexis over 8 to 9 mm, donor lenticule less than 100 microns delivered by Busin glide or pull-through, air / SF6 20 per cent / C3F8 14 per cent tamponade, intraoperative IOP check.
• Immediate post-operative supine positioning — 1 to 2 hours in the day-case unit, with the protocol for the next 24 to 72 hours of strict supine face-up positioning at home clearly explained to the patient and chaperone.
• All topical medications — topical antibiotic for the first week, intensive topical steroid drop on a structured taper for 6 to 12 months, topical IOP-lowering therapy if needed for steroid response. Most patients continue a once-daily maintenance low-dose steroid drop long-term to reduce rejection risk.
• Structured follow-up schedule — day 1, week 1, week 2 to 4, week 6, month 3, month 6, month 12, then 6-monthly or annual surveillance for at least 5 years.
• Re-bubble pathway — protocol for office-based or theatre-based air / SF6 re-injection if the graft has partially or fully detached in the first 1 to 2 weeks; usually included in the per-eye package.
• Long-term endothelial surveillance — serial specular microscopy of the donor endothelium documenting cell density and morphology trend.
• Rejection symptom counselling — explicit patient education to seek immediate review for any eye redness, photophobia, reduced vision or Khodadoust-line keratic precipitates; this is the single most important post-operative patient-empowerment measure.
• Documented air-travel restriction advice — absolute restriction while intra-ocular gas remains (typically 7 days for air, 10 to 14 days for SF6, longer for C3F8).
• Continuity of named consultant — the consultant who consents and operates should lead the post-operative care.

Evidence base — what the trials and registries show

UT-DSAEK has a robust evidence base in the endothelial keratoplasty literature, particularly the comparator data versus DMEK and the long-term donor cornea registries. The headline studies and key registries should be reviewed together:

• DETECT trial (Dunker SL et al., Ophthalmology 2020; n=54 paired-eye randomised) — multi-centre paired-eye randomised controlled trial of DMEK versus UT-DSAEK in patients with bilateral Fuchs endothelial dystrophy. Primary outcome 6-month mean logMAR best corrected visual acuity: DMEK 0.17 (Snellen approximately 20/30) versus UT-DSAEK 0.29 (Snellen approximately 20/40). Patient satisfaction broadly equivalent. Endothelial cell density loss equivalent at 6 months. Re-bubble rate higher with DMEK. The principal landmark RCT comparing the two procedures.
• Busin et al. (Ophthalmology 2013, 2016, 2018) ultra-thin DSAEK series — consecutive series demonstrating UT-DSAEK BCVA of approximately 20/30 to 20/40 at 6 months, 95 per cent graft survival at 5 years and a re-bubble rate of approximately 5 to 10 per cent in experienced hands.
• Cornea Donor Study (CDS) and Cornea Preservation Time Study (CPTS) — long-term US registry data on donor cornea preservation, graft survival and endothelial cell density loss. Five-year graft survival of approximately 90 to 95 per cent for first-graft Fuchs endothelial dystrophy DSAEK; comparable for UT-DSAEK. Donor cornea preservation up to 11 days does not adversely affect 3-year graft survival.
• Lass JH et al. endothelial cell density loss data — serial specular microscopy series documenting endothelial cell density loss of approximately 35 to 45 per cent at 5 years post-DSAEK / UT-DSAEK, slightly higher than DMEK at 30 to 40 per cent over the same period; clinically negligible difference in graft survival.
• NHSBT TES UK Corneal Transplant Database — UK national registry of corneal transplants. Endothelial keratoplasty (DSAEK and DMEK) is now the dominant procedure for endothelial dysfunction (more than 80 per cent of cases for Fuchs and pseudophakic bullous keratopathy indications). Five-year graft survival for first-graft Fuchs in NHS series of approximately 95 per cent.
• Indication-specific outcomes (PBK, failed previous graft, ICE syndrome) — UT-DSAEK in pseudophakic bullous keratopathy has slightly lower 5-year graft survival than in Fuchs (approximately 85 to 90 per cent) due to often more complex eyes; UT-DSAEK after failed previous endothelial keratoplasty or PKP has 5-year survival of approximately 75 to 85 per cent; ICE syndrome outcomes are highly variable depending on associated glaucoma.
• Real-world UK NHS data — Royal College of Ophthalmologists / NHSBT TES audit demonstrates broadly equivalent outcomes between UT-DSAEK and DMEK in standard anterior segments and a clear advantage for UT-DSAEK in complex anterior segments.
• Triple procedure (combined cataract / IOL / endothelial keratoplasty) outcomes — broadly equivalent BCVA and graft survival outcomes to staged sequential procedures, with the advantage of single anaesthetic and single recovery period and avoidance of endothelial cell density loss from a later cataract procedure. The reproducible hyperopic shift of approximately +0.75 to +1.25 dioptres is taken into account in IOL power calculation.
• Hyperopic shift data (Yoo SH et al.; Holz HA et al.) — UT-DSAEK induces a reproducible hyperopic shift of approximately +0.75 to +1.25 dioptres compared with pre-operative refraction; DMEK induces a smaller and less reproducible hyperopic shift.
• AAO Endothelial Keratoplasty Preferred Practice Pattern — recognises DSAEK, UT-DSAEK and DMEK as standard-of-care procedures for endothelial keratoplasty, with UT-DSAEK preferred in complex anterior segments and DMEK preferred in standard eyes where the small additional visual advantage is desired.

In short: UT-DSAEK is a well-established standard-of-care procedure for corneal endothelial dysfunction, with a clearly defined position in the endothelial keratoplasty armamentarium. The DETECT trial documents the 6-month BCVA difference versus DMEK (approximately one to two Snellen lines), and the cornea-donor-study registry data document 5-year graft survival of approximately 95 per cent in first-graft Fuchs. UT-DSAEK is the preferred endothelial keratoplasty in complex anterior segments. The principal counselling points are the 5 to 15 per cent re-bubble rate, the 5 to 10 per cent five-year rejection rate, the reproducible hyperopic shift and the long-term steroid maintenance and rejection-surveillance requirement.

UT-DSAEK versus DMEK versus PKP

Honest head-to-head comparison of the three principal corneal transplant procedures for endothelial dysfunction in 2026:

• UT-DSAEK (ultra-thin DSAEK, donor less than 100 microns) — preserves anterior cornea, donor lenticule is robust and easy to handle, lower re-bubble rate than DMEK (5 to 15 per cent vs 10 to 25 per cent), suitable for complex anterior segments (anterior chamber IOLs, glaucoma drainage devices, post-vitrectomy aphakia, large iridectomies), shallower learning curve, broadly equivalent long-term graft survival. DETECT 6-month BCVA approximately 20/40 (logMAR 0.29). Reproducible hyperopic shift approximately +0.75 to +1.25 dioptres. UK 2026 price approximately £4,500 to 7,000 per eye.
• DMEK (Descemet membrane endothelial keratoplasty, donor 10 to 15 microns) — transplants only Descemet membrane and endothelium with no posterior stroma. DETECT 6-month BCVA approximately 20/30 (logMAR 0.17). Higher re-bubble rate (10 to 25 per cent in experienced hands; substantially higher early in the learning curve). Technically more demanding: donor preparation, scrolling tendency, orientation pitfalls, more difficult in shallow anterior chambers. Not safe in eyes with anterior chamber IOLs, glaucoma drainage devices or post-vitrectomy aphakia. Smaller and less reproducible hyperopic shift. UK 2026 price approximately £5,500 to 8,500 per eye. The right choice for standard eyes in surgeons with established DMEK experience and patients prioritising the slightly better mean visual outcome.
• Penetrating keratoplasty (PKP, full thickness) — the historical procedure; now reserved for combined endothelial and significant anterior stromal pathology, severe corneal scarring, perforation, failed multiple previous endothelial grafts or in eyes where the anterior cornea cannot be preserved. Substantial induced astigmatism, much higher rejection rate (15 to 30 per cent over 5 years), longer recovery, full-thickness sutures that require staged removal, and a larger and more anatomically vulnerable wound. UK 2026 price approximately £6,500 to 10,500.
• Conservative management — hyperosmotic 5 per cent sodium chloride drops or ointment for symptomatic morning corneal oedema; topical IOP optimisation (corneal oedema worsens at higher IOP); hairdryer in the morning to reduce overnight oedema. Appropriate for milder pre-surgical endothelial dysfunction. Long-term surgical decompression is the definitive treatment when symptoms are visually significant.
• Investigational / emerging options — Descemet stripping only (DSO) without donor lenticule in selected central Fuchs cases with healthy peripheral endothelium, intracameral rho-kinase inhibitors (ripasudil, netarsudil) as adjunct, and cultured endothelial cell injection. These are research-stage in 2026 and not standard of care; patients seeking emerging options should be referred to a national tertiary corneal research centre.

Pragmatic 2026 UK pathway: DMEK first-line in straightforward Fuchs endothelial dystrophy or pseudophakic bullous keratopathy in patients with normal anterior segment anatomy and surgeons with established DMEK experience. UT-DSAEK first-line in complex anterior segments, in patients prioritising the lower re-bubble rate, and at centres where DMEK is not routinely offered. PKP reserved for combined endothelial and significant anterior stromal pathology. Triple procedure (cataract + IOL + endothelial keratoplasty) for phakic patients with co-existing cataract. See our DMEK corneal graft and penetrating keratoplasty guides.

Who is UT-DSAEK the right choice for?

UT-DSAEK is the recommended endothelial keratoplasty for adults with visually significant corneal endothelial dysfunction, particularly in eyes where DMEK is technically unsafe. Ideal candidacy:

• Documented Fuchs endothelial corneal dystrophy — confluent guttae on slit-lamp and confocal imaging, central pachymetry typically more than 620 microns or documented pachymetric progression, visually significant symptoms (BCVA reduction, morning corneal oedema with morning blurring, glare and contrast sensitivity loss).
• Pseudophakic bullous keratopathy — corneal endothelial decompensation after complicated cataract surgery, often with epithelial bullae, microcystic oedema and visually significant symptoms.
• Failed previous penetrating keratoplasty or endothelial keratoplasty — with endothelial decompensation in the previous graft. UT-DSAEK after failed PKP or failed previous endothelial keratoplasty is feasible and often the procedure of choice.
• Iridocorneal endothelial (ICE) syndrome with endothelial failure — UT-DSAEK is feasible but outcomes are highly dependent on associated glaucoma.
• Posterior polymorphous corneal dystrophy — with endothelial decompensation.
• Congenital hereditary endothelial dystrophy — selected paediatric and young adult cases.
• Complex anterior segments where DMEK is technically unsafe — anterior chamber IOLs, sulcus-fixated or sutured IOLs, scleral-fixated IOLs, glaucoma drainage devices (tubes), large iridectomies, post-vitrectomy aphakia, hypotony, extensive iris damage. UT-DSAEK is the preferred procedure in these eyes.
• Adults able to lie supine post-operatively — the early-post-operative supine face-up positioning requirement (24 to 72 hours) is critical.
• Adults able to commit to long-term steroid maintenance and rejection surveillance — topical steroid taper over 12 months then once-daily maintenance long-term; rejection symptom education.
• Adults willing to accept the 5 to 15 per cent re-bubble rate — significantly lower than DMEK.
• Adults willing to accept the reproducible hyperopic shift — approximately +0.75 to +1.25 dioptres, requiring a new spectacle prescription at 6 months.
• Adequate fellow-eye function — the staged approach to bilateral disease means the operated eye is functionally blurred for 1 to 2 weeks while the bubble dissipates; adequate fellow-eye function is required.

UT-DSAEK is not the right choice for: patients with significant anterior corneal stromal scarring (penetrating keratoplasty is the appropriate procedure); patients with active infectious keratitis or active intra-ocular inflammation (deferred until quiescent); patients with severe limbal stem cell deficiency (relative contraindication); patients with severe uncontrolled glaucoma where IOP cannot be brought to safe range pre-operatively; patients unable to maintain supine post-operative positioning; patients with severe cognitive impairment limiting safe consent and post-operative compliance; patients with anatomically inadequate anterior chamber depth in some configurations; or patients who can safely have DMEK and prioritise the slightly better mean visual outcome over the lower re-bubble rate of UT-DSAEK.

NHS versus private ultra-thin DSAEK access

UT-DSAEK is commissioned on the NHS through the UK Corneal Transplant Service. Donor tissue is supplied by NHS Blood and Transplant Tissue and Eye Services (NHSBT TES) eye banks in Manchester and Liverpool. Patients meeting NICE / Royal College of Ophthalmologists referral criteria for endothelial transplantation are placed on a tissue-availability list and are typically operated on within 6 to 12 months at a tertiary NHS corneal unit. The patient is followed up at the same NHS unit through the post-operative recovery and long-term surveillance phase. NHS endothelial keratoplasty outcomes (5-year graft survival approximately 95 per cent for first-graft Fuchs) are broadly equivalent to international published series.

Private UT-DSAEK access in 2026 is at selected CQC-registered London corneal centres with consultant corneal surgeons who run an active endothelial keratoplasty practice. The principal advantages of the private pathway are speed (typical consultation-to-surgery time 4 to 8 weeks rather than 6 to 12 months), named-consultant continuity throughout pre-operative work-up, surgery and post-operative care, surgery scheduled on a date of the patient's choosing, and uninterrupted same-team handling of the early-post-operative critical phase (re-bubble pathway, IOP surveillance, steroid taper). Donor tissue is supplied either by NHSBT TES under their tissue-sales policy or imported from accredited European or US eye banks under the Human Tissue Authority licensing framework.

For patients with severe visually significant endothelial decompensation and adequate fellow-eye function, the NHS pathway is entirely reasonable and clinically equivalent. For patients with rapidly progressing disease, those whose work or family circumstances cannot accommodate a 6 to 12 month NHS wait, or those prioritising named-consultant continuity, the private route is sensible. The choice should be discussed with the consultant corneal surgeon on an individualised basis.

Private medical insurance and UT-DSAEK

Yes, generally covered where medically indicated. UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) typically cover ultra-thin DSAEK and the other endothelial keratoplasty procedures (DSAEK, DMEK) where there is a documented diagnosis of corneal endothelial decompensation (Fuchs endothelial dystrophy with confirmed guttae and pachymetric progression on serial imaging, pseudophakic bullous keratopathy after complicated cataract surgery, failed previous graft, ICE syndrome and similar), evidence of visually significant symptoms (visual acuity reduction, morning corneal oedema, glare and contrast sensitivity loss, recurrent epithelial erosions), and a clinical pre-authorisation package supporting the indication. The clinic team prepares the pre-authorisation including a written referral, clinical notes, anterior segment OCT, specular microscopy and pachymetry. Some insurers may require failure or contraindication of conservative measures (5 per cent sodium chloride drops, drying eye drops in the morning, IOP control) before authorising endothelial keratoplasty. The donor tissue cost is part of the surgical package and is usually covered alongside the surgical fees. Pre-authorisation typically takes 1 to 2 weeks; the clinic team coordinates with the insurer to confirm cover before booking.

Risks of ultra-thin DSAEK

Honest counselling on UT-DSAEK-specific risks and the standard intra-ocular surgery risks:

• Graft detachment requiring re-bubble (the principal UT-DSAEK-specific risk) — approximately 5 to 15 per cent of UT-DSAEK grafts partially or fully detach in the first 1 to 2 weeks and require an office-based or theatre-based air or SF6 / C3F8 re-injection. The rate is lower than DMEK (10 to 25 per cent) but higher than penetrating keratoplasty (very rare). Re-bubble is usually quick and successful; rare cases need multiple re-bubbles or surgical re-positioning.
• Allograft rejection — approximately 5 to 10 per cent over 5 years; substantially lower than penetrating keratoplasty (15 to 30 per cent). Presents weeks to months after surgery with eye redness, photophobia, reduced vision and Khodadoust-line keratic precipitates. Treatment is intensive topical, sometimes systemic, corticosteroids; outcome depends on time to treatment and is usually salvageable if treated within 1 to 2 weeks of onset.
• Primary graft failure — 1 to 3 per cent; the graft never functions and corneal oedema does not clear by 6 weeks; managed by repeat UT-DSAEK, DMEK or in rare cases PKP.
• Late graft failure — gradual endothelial decompensation despite a previously functioning graft, typically several years after surgery; 5-year graft survival approximately 95 per cent, 10-year approximately 80 per cent.
• Post-operative IOP rise and steroid-response glaucoma — 5 to 15 per cent; managed with topical pressure-lowering therapy and occasionally with steroid switching (e.g. to fluorometholone or loteprednol).
• Endothelial cell density loss — approximately 35 to 45 per cent at 5 years (slightly higher than DMEK at 30 to 40 per cent but with comparable long-term graft survival).
• Graft dislocation — less than 5 per cent; managed by re-positioning.
• Reproducible hyperopic shift — approximately +0.75 to +1.25 dioptres; taken into account in IOL planning for triple procedure; corrected with new spectacles at 6 months.
• Secondary cataract progression in phakic patients — common after endothelial keratoplasty due to lens proximity to the air bubble; combined triple procedure (cataract + IOL + UT-DSAEK) is usually preferred in phakic patients aged over 50.
• Infection / endophthalmitis — less than 0.1 per cent per procedure with povidone iodine prep; treated with immediate intravitreal antibiotics by a vitreoretinal surgeon if it occurs.
• Cystoid macular oedema — 2 to 5 per cent; managed with topical NSAID and steroid.
• Rhegmatogenous retinal detachment — less than 1 per cent; managed by vitreoretinal surgery.
• Pupillary block — rare; associated with too large or trapped air / gas bubble; managed by partial gas release.
• Donor tissue concerns — transmission of donor disease is exceedingly rare given the screening (HIV, hepatitis B and C, syphilis and others); donor cornea endothelial cell count is documented before transplant.
• Long-term commitment — structured 12-month follow-up plus long-term annual surveillance and once-daily maintenance topical steroid drop to reduce rejection risk; rejection symptom counselling reinforced at every visit.

Recovery after ultra-thin DSAEK

The UT-DSAEK procedure itself takes approximately 30 to 45 minutes of theatre time. Total day-case time including check-in, anaesthetic prep, surgery and immediate post-operative recovery is approximately 4 to 6 hours. Same-day discharge is routine. The patient must arrange transport home with an adult companion; driving and operating heavy machinery are not permitted for at least 24 hours and longer if vision is significantly blurred.

First 24 to 72 hours. Strict supine face-up positioning at home with regular bathroom and meal breaks only; the centre's specific positioning protocol must be followed exactly. Topical steroid every 1 to 2 hours during waking hours, topical antibiotic four times daily. Mild discomfort, foreign body sensation, light sensitivity and significantly blurred vision (because of the air or gas bubble in the anterior chamber) are normal. The patient must not press on or rub the eye and must avoid bending forward.

First 1 to 2 weeks. Vision is blurred while the gas bubble dissipates (typically 7 days for air, 10 to 14 days for SF6, longer for C3F8). The patient is reviewed by the operating consultant at day 1 and week 1 to confirm graft adherence; approximately 5 to 15 per cent of grafts need a re-bubble in this window. Air travel is absolutely restricted while intra-ocular gas remains (the trapped gas expands at altitude, raises IOP and can cause graft failure or pupillary block).

Weeks 2 to 12. Steady visual improvement as the corneal stroma deturgesces; reviewed at weeks 2 to 4, 6 weeks and 3 months. Topical steroid is tapered from hourly to four times a day by 1 month and twice a day by 3 months. IOP is monitored for steroid response. Most patients see meaningful improvement by 6 weeks.

Months 3 to 12. Continued slow visual improvement; final BCVA usually reached by 6 months in straightforward cases. The reproducible hyperopic shift of approximately +0.75 to +1.25 dioptres means a new spectacle prescription is dispensed at 6 to 12 months once refraction is stable. Topical steroid is tapered to once-daily maintenance and continued long-term to reduce rejection risk.

Long-term. Annual consultant review with slit-lamp examination, IOP, central pachymetry, anterior segment OCT and specular microscopy of the donor endothelium documenting cell density and morphology trend. Rejection symptom counselling reinforced at every visit (eye redness, photophobia, reduced vision, Khodadoust-line keratic precipitates). Patients are encouraged to seek immediate review for any of these symptoms; prompt treatment of acute rejection within 1 to 2 weeks of onset is usually graft-saving. The 0800 852 7782 advice line is available throughout the long-term recovery journey.

How to choose a UK clinic for ultra-thin DSAEK

• Consultant corneal credentials — UK GMC registration with corneal and external eye disease fellowship; active endothelial keratoplasty practice (DSAEK, UT-DSAEK and DMEK) of at least 30 to 50 cases per year; documented complex-anterior-segment experience.
• CQC-registered ophthalmic operating theatre — with laminar flow, dedicated ophthalmic surgical equipment, experienced theatre nursing team and on-site anaesthetic support.
• Imaging quality — high-resolution anterior segment OCT (Casia, Spectralis, or comparable), specular microscopy of the corneal endothelium, Scheimpflug tomography (Pentacam, or comparable), and corneal pachymetry.
• Donor tissue pathway — documented relationship with NHSBT TES Manchester / Liverpool or with an accredited European or US eye bank under Human Tissue Authority licensing. Pre-cut ultra-thin specification preferred.
• Same-team continuity — the consultant who consents and operates should personally lead the day 1, week 1, week 2 to 4 and 3-month reviews; the early-post-operative period is the highest-risk window for graft detachment.
• Re-bubble pathway — protocol for office-based or theatre-based air or SF6 re-injection if needed in the first 1 to 2 weeks; usually included in the per-eye package without additional charge.
• Itemised written quotation — consultant fee, imaging, donor tissue, surgery, the air or gas tamponade, all post-operative medications and the follow-up schedule should be itemised; total per-eye price clearly stated up-front.
• Both UT-DSAEK and DMEK available — allows per-case selection on anterior segment anatomy and patient priorities rather than constrained by what the surgeon offers.
• Triple procedure capability — combined cataract surgery and endothelial keratoplasty for phakic patients with co-existing visually significant cataract.
• Long-term endothelial surveillance — serial specular microscopy of the donor endothelium and structured 5-year follow-up plan.
• 24-hour advice line — for new pain, vision change or rejection-suspicious symptoms after discharge.

Frequently asked questions

How much does private ultra-thin DSAEK cost in the UK in 2026?

UK 2026 self-pay private UT-DSAEK is £4,500–£7,000 per eye, all-inclusive at CQC-registered London corneal centres. The fee covers the consultant assessment, imaging, the eye bank donor tissue, the day-case surgery, the air or gas tamponade, all topical medications for the first 6 months and a structured 12-month follow-up schedule. Triple procedure (UT-DSAEK + cataract + IOL) is £6,500–£9,500.

What is ultra-thin DSAEK and how does it differ from regular DSAEK?

DSAEK replaces only the failed inner endothelial layer of the cornea plus a thin posterior stromal layer. Conventional DSAEK uses a donor lenticule 130 to 200 microns thick. Ultra-thin DSAEK uses a lenticule prepared to less than 100 microns by double-pass microkeratome dissection; the thinner donor optimises visual outcome, narrowing but not eliminating the visual advantage of DMEK.

UT-DSAEK versus DMEK — which is better?

In standard anterior segments, DMEK produces slightly faster visual recovery and slightly better mean BCVA (DETECT 6-month BCVA approximately 20/30 vs UT-DSAEK 20/40). However DMEK is technically more demanding, has a higher re-bubble rate and is unsafe in complex anterior segments (anterior chamber IOLs, glaucoma drainage devices, post-vitrectomy aphakia). UT-DSAEK is preferred in these complex eyes and remains a reasonable first choice for surgeons earlier on the DMEK learning curve or patients prioritising the lower re-bubble rate. See our DMEK guide.

Who is a good candidate for UT-DSAEK?

Adults with visually significant corneal endothelial dysfunction: Fuchs endothelial corneal dystrophy with confluent guttae and pachymetric progression, pseudophakic bullous keratopathy, failed previous graft, ICE syndrome, posterior polymorphous corneal dystrophy or congenital hereditary endothelial dystrophy. UT-DSAEK is particularly favoured in eyes with complex anterior segments where DMEK is technically unsafe.

Does the NHS pay for UT-DSAEK?

Yes. Endothelial keratoplasty is commissioned on the NHS through the UK Corneal Transplant Service with donor tissue from NHSBT TES Manchester / Liverpool. Typical waits are 6 to 12 months. Private UT-DSAEK is chosen for a faster pathway, named-consultant continuity and same-team post-operative care.

What are the risks of UT-DSAEK?

Graft detachment requiring re-bubble in approximately 5 to 15 per cent, allograft rejection in 5 to 10 per cent over 5 years, primary graft failure in 1 to 3 per cent, steroid-response glaucoma in 5 to 15 per cent, endothelial cell density loss of approximately 35 to 45 per cent at 5 years, reproducible hyperopic shift of approximately +0.75 to +1.25 dioptres, secondary cataract progression in phakic patients, rare endophthalmitis (less than 0.1 per cent) and rare retinal detachment (less than 1 per cent).

How long does the surgery take?

UT-DSAEK is a day-case procedure with theatre time approximately 30 to 45 minutes (60 to 90 minutes for triple procedure combined with cataract surgery). The default anaesthetic is topical or sub-Tenon's local anaesthetic with mild oral sedation. Total day-case time is approximately 4 to 6 hours including immediate post-operative supine positioning.

How long is the recovery and when can I see properly?

Visual recovery is gradual. Vision is blurred for the first 1 to 2 weeks while the air or gas bubble dissipates. Meaningful improvement by 6 weeks. Final BCVA usually by 6 months. Long-term topical steroid maintenance and structured surveillance are required.

Will my private medical insurance pay for UT-DSAEK?

Generally yes where medically indicated. UK private medical insurers cover endothelial keratoplasty (DSAEK, UT-DSAEK, DMEK) with documented diagnosis and clinical pre-authorisation. The clinic team prepares the pre-authorisation package; the donor tissue is part of the surgical package and is usually covered.

Can I have both eyes done at the same time?

No. Bilateral simultaneous UT-DSAEK is not the standard of care. The two eyes are staged 4 to 6 weeks apart at minimum, more commonly 2 to 3 months apart, to confirm satisfactory outcome and absence of complications in the first eye before committing the second.

What if my graft fails or rejects?

Early detachment is managed by office-based or theatre-based air or SF6 re-injection (re-bubble); approximately 5 to 15 per cent of UT-DSAEK grafts need at least one re-bubble. Acute rejection is treated promptly with intensive topical, sometimes systemic, corticosteroids and is usually salvageable if treated within 1 to 2 weeks of onset. Primary or late graft failure is managed by repeat UT-DSAEK, DMEK or PKP.

What are the alternatives to UT-DSAEK?

DMEK in standard eyes for slightly better visual outcome; conventional DSAEK where ultra-thin preparation is technically difficult; penetrating keratoplasty for combined endothelial and significant anterior stromal pathology. Conservative pre-surgical management with hyperosmotic 5 per cent sodium chloride drops, IOP optimisation and morning hairdryer for mild Fuchs.

Where does the donor cornea come from?

NHS Blood and Transplant Tissue and Eye Services (NHSBT TES) Manchester or Liverpool eye banks (NHS and private surgery under their tissue-sales policy) or imported from accredited European or US eye banks under Human Tissue Authority licensing. All tissue is screened for transmissible disease and endothelial cell count is assessed pre-operatively.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with corneal and external eye disease subspecialty interest. Pricing reflects a CQC-registered UK corneal sample audited against published 2025 to 2026 self-pay tariffs from the major UK private corneal providers and the NHSBT TES tissue-sales policy. Clinical statements are anchored on:

• Dunker SL, Dickman MM, Wisse RPL, et al. Descemet membrane endothelial keratoplasty versus ultrathin Descemet stripping automated endothelial keratoplasty: a multicenter randomized controlled clinical trial (DETECT). Ophthalmology 2020.
• Busin M, Madi S, Santorum P, et al. Ultrathin Descemet's stripping automated endothelial keratoplasty with the microkeratome double-pass technique: two-year outcomes. Ophthalmology 2013 / 2016 / 2018 series.
• Lass JH, Benetz BA, Patel SV, et al. Donor, recipient, and operative factors associated with increased endothelial cell loss in the cornea preservation time study. JAMA Ophthalmology / Cornea.
• Cornea Donor Study Investigator Group. The effect of donor age on penetrating keratoplasty outcomes (CDS): 10-year follow-up. Ophthalmology.
• Cornea Preservation Time Study Group. Effect of cornea preservation time on long-term graft success.
• Yoo SH, Holz HA. Hyperopic shift after Descemet stripping automated endothelial keratoplasty. Cornea / Journal of Cataract and Refractive Surgery literature.
• Royal College of Ophthalmologists guidance on the UK Corneal Transplant Service.
• NHS Blood and Transplant Tissue and Eye Services (NHSBT TES) operating procedures and tissue-sales policy.
• Human Tissue Authority licensing framework for imported human ocular tissue.
• Eye Bank Association of America medical standards.
• European Eye Bank Association technical guidelines.
• American Academy of Ophthalmology Endothelial Keratoplasty Preferred Practice Pattern.
• Care Quality Commission (CQC) inspection reports for major UK corneal centres.
• General Medical Council (GMC) Good Medical Practice and consent guidance.

This page is editorial and educational. It is not personalised medical advice. UT-DSAEK suitability can only be confirmed by an in-person corneal consultation with anterior segment OCT, specular microscopy and pachymetry.

Book your UK ultra-thin DSAEK / corneal graft consultation

Speak directly to a UK GMC-registered consultant corneal surgeon with corneal and external eye disease subspecialty fellowship and an active endothelial keratoplasty practice (UT-DSAEK and DMEK). Same-week consultation slots are usually available. Anterior segment OCT, specular microscopy, pachymetry and a written treatment-options plan are included in the consultation. Confidential, no-obligation review of whether UT-DSAEK, DMEK, penetrating keratoplasty or continued conservative management is right for your eye, with full discussion of the donor tissue pathway, surgical technique, recovery profile and long-term graft surveillance.

Related reading: DMEK corneal graft · Penetrating keratoplasty · Fuchs endothelial dystrophy · Pseudophakic bullous keratopathy · Corneal dystrophies · Corneal transplant overview